There are conflicting reports on the propensity of topical 1B blockers to produce corneal anaesthesia. We measured corneal sensitivity thresholds quantitatively for 10 minutes following the administration of one drop of topical timolol maleate (0.5%), betaxolol hydrochloride (0.5%), or saline in 30 eyes of 18 normal subjects in a randomised, doublemasked study. Most subjects had insignificant changes in corneal sensitivity thresholds. We identified, however, a subgroup of four subjects (five eyes) that had a marked and prolonged increase of corneal sensitivity threshold (corneal anaesthesia) after timolol (three eyes) and betaxolol (two eyes). The group mean age of these 'responders' (49.0 years) was significantly greater (p<0005) than that of the non-responders (35.0). We recommend periodic measurements of corneal sensitivity in older patients receiving topical timolol or betaxolol, especially when given in higher concentrations, to identify responders, who may be at risk of developing keratitis.
Blockers are first line drugs for topical therapy ofprimary open-angle glaucoma. They lower the intraocular pressure mainly by depressing the production of aqueous. Local anaesthetic effects of blockers may be from membrane stabilisation'2 or inhibition of corneal epithelial chloride transport,3 which is independent of their 13 blocking effect.
Timolol maleate, the first topical ,3 blocker available in the United States, is a non-selective P I and f2-adrenergic antagonist. Van Buskirk4 reported corneal anaesthesia in four of25 patients taking topical timolol and in a separate study' observed that, of 547 reports of adverse ocular reactions to topical timolol, 20 mentioned superficial punctate keratitis, with coexistent corneal anaesthesia in eight. More recent studies have conflicted in regard to the incidence and severity of corneal anaesthesia produced by topical timolol.i1" Betaxolol hydrochloride, a newer, selective adrenergic antagonist has been observed by some authors to cause mild, transient corneal anaesthesia after topical use,'2'3 while this was not observed by others." '6 We conducted a randomised, double-masked, clinical trial measuring the quantitative corneal anaesthetic side effects of the use of one drop of topical timolol 0 5% and betaxolol 0 5%.
Materials and methods
We studied 30 eyes of 18 normal subjects. We excluded subjects who had previous ocular surgery, photocoagulation, trauma, corneal inflammation, or infection; those who had used topical or systemic medicines known to alter corneal sensitivity, pregnant women, contact lens wearers, diabetics, and patients older than 60. (Persons above 60 years of age' may have decreased corneal sensitivity.)
Twenty-five subjects were enrolled in this study. Five were excluded because of excessive eye movement and/or inconsistent measurements during baseline threshold testing. Two other patients failed to keep scheduled appointments.
We dynamically measured corneal sensitivity thresholds using the electronic optical aesthesiometer developed by Draeger. During measurement the stimulus body length remains constant and in contact with the cornea, while the exerted force is expotentially increased by the investigator, which permits all measurements to be completed within the physiological blink interval. When subjects perceive a touch sensation, they depress a button that automatically terminates stimulus body contact with the cornea, and the threshold force (between 0 and 999x 10Vnewtons) is displayed on a digital LED indicator. All threshold measurements were performed by one investigator (SSW).
Ten subjects received one drug (timolol, betaxolol, or saline), four subjects received two drugs, and four subjects received three drugs during the course of the study, in a randomised, double masked fashion. (Three subjects complained of stinging after betaxolol administration, thereby unmasking the drop to the investigator) In the multiple drug group a two-week washout period followed drug administrations. A subject never received the same drug more than once during the study.
The timolol group consisted of 10 subjects, eight females and two males, with a mean age of 41 2 (range 27-53) ( Table I ). Seven were black; three were white. The betaxolol group consisted of nine subjects, six females and three males, with a mean age of 35-9 (range 27-55) ( Table I) . Five were black, four were white. The saline control group consisted of 11 subjects, 10 females and one male, with a mean age of 39-1 (range 29-49) ( Table I) . Eight were black, three were white.
The baseline threshold was determined 1 This threshold was assumed to be the average of the preceding and subsequent measurement. Paired t testing comparing thresholds at time x and time x+ 1 minutes within drug groups confirmed the validity of this assumption. Relative change from baseline at time x minutes = threshold at time x minutes -threshold at baseline threshold at baseline for 5 seconds, corneal sensitivity thresholds were remeasured at the same position at 1-minute intervals for 10 minutes. The measurements were continued for 20 minutes if thresholds had not returned to baseline at 10 minutes. The subjects were required to blink between measurements to prevent corneal desiccation.
STATISTICAL ANALYSIS
At each measurement period (minutes 1 to 10 after drug instillation) we compared the mean relative change in corneal sensitivity thresholds* in the timolol and betaxolol groups to a saline control group using t tests. We analysed intragroup changes in relative corneal sensitivity thresholds by F ratio tests. We compared mean ages of responders and non-responders in the timolol and betaxolol groups by t tests. We considered p%0 05 to be significant.
Results
There was no significant change in relative corneal sensitivity thresholds in any of the drug groups (p=0-015), and at no time interval (1 to 10 minutes) after drug instillation was there any significant difference in mean relative changes in thresholds among the three drug groups. However, three eyes tested with timolol and two eyes tested with betaxolol showed marked corneal *Relative change from baseline at time x minutes= threshold at time x minutes -threshold at baseline threshold at baseline
anaesthesia, which persisted for longer than 10 minutes in all cases.
In the saline group relative changes in thresholds were mild and transient.* Responders (subjects who had at least a fivefold relative increase in corneal sensitivity threshold which persisted for at least 5 minutes) had the threshold of their untreated contralateral eye measured at 10 minutes. This was done to ensure that corneal anaesthetic effects produced in the treated eye were produced by the drug and were not due to patient fatigue or other non-drugrelated factors. All responders had thresholds in the untreated eye that were not significantly different from baseline thresholds in the treated eye, lending support to observer reliability.
One responder received all three drops during the course of the study (Fig 1) . After timolol administration her relative change in thresholds included 8-9 at 1 minute and a peak of 26-8 at 13 minutes. A marked corneal anaesthetic effect (relative change in threshold of persisted at 20 minutes. After receiving betaxolol this subject had the following relative change in thresholds: 110.0 at 1 and 10 minutes and 25 6 at 20 minutes. After saline administration this subject had relative threshold changes of4-7 at 5 minutes and 9-0 at 6 minutes, but the remainder of the measured thresholds were approximately equal to baseline.
A second responder received both timolol and saline during the course of the study. Relative threshold changes after timolol were 231-5 at 2 minutes, 394'5 at 3 minutes, and 9-0 at 20 minutes. After saline testing, relative changes in thresholds were 5 1 at 4 minutes, 15-8 at 6 minutes, and 1'3 at 10 minutes. The third responder received timolol only and had relative threshold changes of 16-6 at 4 minutes, a peak of 21-7 at 5 minutes, and a return to baseline at 19 minutes. The fourth responder received only betaxolol and had relative threshold changes which peaked at 13 5 at 3 minutes, with a return to baseline by 19 minutes.
The responders (timolol and betaxolol groups combined) ranged in age from 39 to 53 with a mean age of 49-0 (SD 6-2). The non-responders differed significantly, they ranged in age from 27 to 52 and had a mean age of 35-0 (SD (<0 005).
*Differing baseline values obtained from the same subject on different days, and variability in threshold values following saline administrations, were presumed to be due to the inexact placing of the stimulus body on the cornea, and variation in subject response times. Minutes after drug instillation Figure 1 : Note the marked and prolonged corneal anaesthesia in this subject after timolol, and after betaxolol administration.
Effects oftopical timolol (0O5%) and betaxolol (0O5%) on More recent reports"6' 32 have conflicted with regard to the incidence and severity of corneal anaesthetic side effects produced by topical timolol and betaxolol. A variety of methods were used in these studies to measure corneal sensitivity (Table II) . Draeger3 used the aesthesiometer employed in the present study and found transient corneal anaesthetic effects following a one-time administration of topical timolol, but only in subjects older than 40. He also noted subjects in whom marked and prolonged corneal anaesthetic effect occurred following administration of several different ,B blockers. He postulated a genetically determined enzyme variation to explain these patients' susceptibility to blocker induced corneal anaesthesia.
We did not detect in 18 subjects (30 eyes) significant relative change in corneal sensitivity thresholds from baseline in either the timolol or the betaxolol groups in comparison with placebo (saline) group. We compared relative changes in thresholds at each measurement interval (1-10 minutes after drug administration) between the three drug groups, and found no point at which a significant intergroup difference existed.
We identified a subgroup of four subjects (five eyes) that showed marked and prolonged corneal anaesthetic effects after topical timolol (three eyes) and topical betaxolol (two eyes). One The indentification in this study of a subgroup of generally older patients showing marked and prolonged corneal anaesthetic side effects after topical timolol 0-5% confirmed previous investigations by Van Buskirk,4 Spinelli and associates,7 and Draeger.1 In addition, we demonstrated that this effect may also occur after topical betaxolol 0-5% administration.
The failure of many previous reports to document these corneal anaesthetic side effects of topical timolol and betaxolol may be attributed in some instances to use of lower concentrations of topical IB blockers, use of less sensitive methods to measure corneal sensitivity, and to study populations which consisted of mostly young subjects with few or no responders.
We recommend performing periodic corneal aesthesiometry in patients receiving topical timolol and betaxolol to identify responders. More frequent monitoring is suggested in patients with pre-existing corneal hypoaesthesia, in older patients, and in those receiving higher concentrations of these topical blockers. If a significant keratitis is shown to occur frequently in responders treated with topical ,3 blockers, therapy with an alternative class of intraocular pressure lowering medication may be preferable in these susceptible patients.
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